March 15, 2021

Andrew Campbell 

Germany, Belgium, and Sweden have approved the Oxford-AstraZeneca vaccine for all adults but only suspended the jab to those above 65. Ireland and the Netherlands on March 14 suspended their rollouts of the AstraZeneca vaccine over the risk of post-jab blood clots. However, an AstraZeneca spokesman assured that no evidence of increased risk of blood clot conditions was shown after analyzing doses over 17 million cases. The spokesman revealed the reported numbers of blood clot incidents for COVID-19 Vaccine AstraZeneca are lower than the number in the natural, unvaccinated population.

Since the emergence of COVID disease in China in late 2019, vaccinations play a major role in safeguarding the world population from the deadly pandemic that has taken more than 2.6 million lives. According to the WHO-backed COVAX initiative, which ensures COVID-19 vaccines available to the world, AstraZeneca is among the cheapest deliveries to poorer nations. The Oxford-AstraZeneca vaccine has been reportedly in short supply within the EU with production shortfalls at plants in Belgium and the Netherlands. Meanwhile, AstraZeneca acknowledged that production problems and export restrictions would delay its EU vaccine deliveries.

French Prime Minister Jean Castex announced on March 14 that France would not suspend the rollout and decided to continue with the AstraZeneca vaccine. Heurged people have confidence in the AstraZeneca vaccine. Deciding to carry on using the AstraZeneca vaccine, he warned of the danger of leaving a large population unprotected from the COVID pandemic.

Photo:Webshot.